P3.01-76 Clinical Background and Response to Chemotherapy in NSCLC Patients With MET Exon14 Skipping Mutation or High MET Gene Copy Number

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.1636
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P3.01-60 a Novel MET D1246H Mutation After Progression of EGFR-TKI/MET Inhibitor Combined Therapy in a NSCLC Patient With Acquired MET Amplification

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

OA12.01 Phase II Data for the MET Inhibitor Tepotinib in Patients With Advanced NSCLC and MET Exon 14-Skipping Mutations

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MA21.03 Heterogeneity in MET Copy Number and Intratumoural Subsets in Pleomorphic Lung Carcinoma: Implications for MET Directed Therapy in NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MET in Gastric Carcinomas: Comparison Between Protein Expression and Gene Copy Number and Impact on Clinical Outcome

British Journal of Cancer
Cancer ResearchOncology
2012English

P3.01-44 CYFRA 21-1 as a Predictor to Response to Chemotherapy and Overall Survival in Patients With Advanced NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-51 Outcomes With Systemic Chemotherapy in Advanced NSCLC Patients With Performance Status 2 and Above and Without Driver Mutation

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

OA06 Tepotinib in Non-Small Cell Lung Cancer With MET Exon 14-Skipping Mutations or MET Amplification: A Phase 2 Trial in Progress

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Characterization of 298 Patients With Lung Cancer Harboring MET Exon 14 Skipping Alterations

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2016English

Combination of EGFR-TKIs With Chemotherapy Versus Chemotherapy or EGFR-TKIs Alone in Advanced NSCLC Patients With EGFR Mutation

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy